Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Nat Med. 2016 Feb;22(2):128–134. doi: 10.1038/nm.4036

Figure 2. EZH2 as a therapeutic target in cancer.

Figure 2

a. The roles of EZH2 mediated transcriptional silencing are context specific. For cell types in which its hyperactivity drives oncogenesis, contributions from silencing of lineage specification genes, the tumor suppressor Rb and DNA repair genes have been identified. b. Cancers harboring SWI/SNF mutations and gain-of-function EZH2 mutations confer dependency on EZH2 inhibition. Early pre-clinical evidence suggests potential benefit of combination therapy with an EZH2 inhibitor. At least in the case of cancers driven by SWI/SNF mutation, Ras pathway mutations can confer resistance to EZH2 inhibition.